Cardiovascular diseases especially heart failure (HF) are one of the biggest challenges for modern medicine. There is a strong need to develop a new therapy that can manage heart failure and also reduces its complications due to the increasing number of people suffering from this disease. In recent years, various efforts have been made for improving the primary outcome in HF patients. Several clinical studies have shown the potential of various agents in reducing mortality and morbidity thereby shifting the use of pharmacological approaches.